A5069332020- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Mesenchymal stem cell research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Polyomavirus and related diseases
- Clinical Nutrition and Gastroenterology
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- CNS Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Blood groups and transfusion
- Complement system in diseases
MedStar Georgetown University Hospital
2025
Georgetown University Medical Center
2024
Georgetown University
2023-2024
Rochester General Hospital
2022
Unity Health System
2021
New York Oncology Hematology
2021
Icahn School of Medicine at Mount Sinai
2015-2020
Tisch Cancer Institute
2018-2019
Tisch Hospital
2019
Yahoo (United Kingdom)
2019
Highlights•Staging GVHD symptoms varies among BMT centers because of different practices.•Different staging practices make comparing results between studies difficult.•Standardized detailed guidance was developed by a consortium.•Increased uniformity may improve clinical trial reproducibility.AbstractAcute graft-versus-host disease (GVHD) remains leading cause morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The greatly transplant is frequently not...
BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to onset GVHD symptoms.
Acute graft-versus-host disease (aGVHD) remains a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab could help prevent aGVHD by inhibiting the migration both naive and activated lymphocytes into gut-associated lymphoid tissues lamina propria. We carried out phase 1b, open-label, dose-finding study in adults undergoing allo-HSCT to evaluate tolerability, safety, pharmacokinetics vedolizumab, its effectiveness reducing aGVHD. IV vedolizumab...
Therapeutic Plasma Exchange (TPE) remains a primary therapy for addressing circulating donor-specific antibodies (DSA) against mismatched Human Leukocyte Antigens (HLA), which pose significant challenge to successful transplantation of solid organs and hematopoietic cells. In this study, we evaluated the response five TPE sessions in patients undergoing desensitization, as well who developed antibody-mediated rejection (AMR) post-transplant. Sera collected before after each session was...
Amphiregulin (AREG) is an epidermal growth factor receptor ligand that can restore integrity to damaged intestinal mucosa in murine models of acute graft-versus-host disease (aGVHD). We previously reported circulating AREG elevated late-onset aGVHD (occurring after 100 days posttransplant), but its clinical relevance the context risk unknown. measured 251 onset blood samples from Blood and Marrow Clinical Trials Network (BMT CTN) primary treatment trials determined their association with...
Abstract Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there no approved treatments SR aGvHD. Vedolizumab is treatment of ulcerative colitis and Crohn’s disease, may be effective intestinal We conducted phase 2a trial (NCT02993783) to evaluate the clinical efficacy, tolerability, safety vedolizumab 300...
The rupture of the anterolateral papillary muscle is less common than posteromedial since has dual blood supplies, while a single supply.We present case report 42 year old male presenting with heart failure being diagnosed to have mitral regurgitation from partial due coronary artery disease. patient underwent valve replacement and concomitant bypass grafting first second obtuse marginal arteries.Acute can be precipitated by acute myocardial infarction muscle.
Graft-versus-host disease (GVHD) continues to be the major lethal complication of allogeneic hematopoietic stem cell transplantation (HCT) but standard care, high dose steroids, has not changed in 40 years. Approximately 50% GVHD patients will develop steroid refractory disease, typically involving gastrointestinal (GI) tract, which a very poor prognosis. Newly developed biomarker-based risk scores provide first opportunity treat at onset symptoms according failure. Furthermore, improvements...
Abstract Background: Aging, smoking and germline predisposition are known to accelerate leukemogenesis. However, the ability for myeloid clonal pathogenic variants (MCPV) elicit an antigen-driven host antileukemia immune response is not well characterized. A better understanding on how cellular immunity selectively discriminates leukemia-related “neopeptides” could uncover mechanisms supporting tumor genome evolution. Methods: 122 patients with acute myelogenous leukemia (AML) were included...
The management of elderly patients diagnosed with acute myelogenous leukemia (AML) is complicated by high relapse risk and comorbidities that often preclude access to allogeneic hematopoietic cellular transplantation (allo-HCT). In recent years, fast-paced FDA drug approval has reshaped the therapeutic landscape, modest, albeit promising improvement in survival. Still, AML outcomes remain unacceptably unfavorable highlighting need for better understanding disease biology tailored strategies....